285 related articles for article (PubMed ID: 28993169)
21. A 3D printed bilayer oral solid dosage form combining metformin for prolonged and glimepiride for immediate drug delivery.
Gioumouxouzis CI; Baklavaridis A; Katsamenis OL; Markopoulou CK; Bouropoulos N; Tzetzis D; Fatouros DG
Eur J Pharm Sci; 2018 Jul; 120():40-52. PubMed ID: 29678613
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in HIV-infected Indian children.
Mukherjee A; Velpandian T; Singla M; Kanhiya K; Kabra SK; Lodha R
Int J Tuberc Lung Dis; 2016 May; 20(5):666-72. PubMed ID: 27084822
[TBL] [Abstract][Full Text] [Related]
23. Tailored release drug delivery system for rifampicin and isoniazid for enhanced bioavailability of rifampicin.
Avachat AM; Bhise SB
Pharm Dev Technol; 2011 Apr; 16(2):127-36. PubMed ID: 20105081
[TBL] [Abstract][Full Text] [Related]
24. Oral bioavailability of rifampicin, isoniazid, ethambutol, and pyrazinamide in a 4-drug fixed-dose combination compared with the separate formulations in healthy Chinese male volunteers.
Xu J; Jin H; Zhu H; Zheng M; Wang B; Liu C; Chen M; Zhou L; Zhao W; Fu L; Lu Y
Clin Ther; 2013 Feb; 35(2):161-8. PubMed ID: 23410999
[TBL] [Abstract][Full Text] [Related]
25. A novel solid dosage form of rifampicin and isoniazid with improved functionality.
Gohel MC; Sarvaiya KG
AAPS PharmSciTech; 2007 Aug; 8(3):E68. PubMed ID: 17915818
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic drug monitoring of isoniazid and rifampicin during anti-tuberculosis treatment in Auckland, New Zealand.
Maze MJ; Paynter J; Chiu W; Hu R; Nisbet M; Lewis C
Int J Tuberc Lung Dis; 2016 Jul; 20(7):955-60. PubMed ID: 27287650
[TBL] [Abstract][Full Text] [Related]
27. Development and characterization of spray-dried porous nanoaggregates for pulmonary delivery of anti-tubercular drugs.
Kaur R; Garg T; Malik B; Gupta UD; Gupta P; Rath G; Goyal AK
Drug Deliv; 2016; 23(3):882-7. PubMed ID: 24870203
[TBL] [Abstract][Full Text] [Related]
28. 3D printing of high drug loaded dosage forms using thermoplastic polyurethanes.
Verstraete G; Samaro A; Grymonpré W; Vanhoorne V; Van Snick B; Boone MN; Hellemans T; Van Hoorebeke L; Remon JP; Vervaet C
Int J Pharm; 2018 Jan; 536(1):318-325. PubMed ID: 29217471
[TBL] [Abstract][Full Text] [Related]
29. A bioactive implant in situ and long-term releases combined drugs for treatment of osteoarticular tuberculosis.
Zhou CX; Li L; Ma YG; Li BN; Li G; Zhou Z; Shi F; Weng J; Zhang C; Wang F; Cui X; Wang L; Wang H
Biomaterials; 2018 Sep; 176():50-59. PubMed ID: 29857274
[TBL] [Abstract][Full Text] [Related]
30. Dosage of isoniazid and rifampicin poorly predicts drug exposure in tuberculosis patients.
Sturkenboom MG; Akkerman OW; van Altena R; de Lange WC; Kosterink JG; van der Werf TS; Alffenaar JC
Eur Respir J; 2016 Oct; 48(4):1237-1239. PubMed ID: 27492836
[No Abstract] [Full Text] [Related]
31. A Lower Temperature FDM 3D Printing for the Manufacture of Patient-Specific Immediate Release Tablets.
Okwuosa TC; Stefaniak D; Arafat B; Isreb A; Wan KW; Alhnan MA
Pharm Res; 2016 Nov; 33(11):2704-12. PubMed ID: 27506424
[TBL] [Abstract][Full Text] [Related]
32. Tailored on demand anti-coagulant dosing: An in vitro and in vivo evaluation of 3D printed purpose-designed oral dosage forms.
Arafat B; Qinna N; Cieszynska M; Forbes RT; Alhnan MA
Eur J Pharm Biopharm; 2018 Jul; 128():282-289. PubMed ID: 29673871
[TBL] [Abstract][Full Text] [Related]
33. Coupling 3D printing with hot-melt extrusion to produce controlled-release tablets.
Zhang J; Feng X; Patil H; Tiwari RV; Repka MA
Int J Pharm; 2017 Mar; 519(1-2):186-197. PubMed ID: 28017768
[TBL] [Abstract][Full Text] [Related]
34. Pyrazinamide serum levels in childhood tuberculosis.
Thee S; Detjen A; Wahn U; Magdorf K
Int J Tuberc Lung Dis; 2008 Sep; 12(9):1099-101. PubMed ID: 18713511
[TBL] [Abstract][Full Text] [Related]
35. A comprehensive overview of extended release oral dosage forms manufactured through hot melt extrusion and its combination with 3D printing.
Nashed N; Lam M; Nokhodchi A
Int J Pharm; 2021 Mar; 596():120237. PubMed ID: 33484928
[TBL] [Abstract][Full Text] [Related]
36. Development and optimization of polymeric nanoparticles of antitubercular drugs using central composite factorial design.
Chawla R; Jaiswal S; Mishra B
Expert Opin Drug Deliv; 2014 Jan; 11(1):31-43. PubMed ID: 23802585
[TBL] [Abstract][Full Text] [Related]
37. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis.
Pandey R; Khuller GK
Tuberculosis (Edinb); 2005 Jul; 85(4):227-34. PubMed ID: 15922668
[TBL] [Abstract][Full Text] [Related]
38. [Design of Spray-dried Porous Particles for Sugar-based Dry Powder Inhaler Formulation].
Kadota K
Yakugaku Zasshi; 2018; 138(9):1163-1167. PubMed ID: 30175760
[TBL] [Abstract][Full Text] [Related]
39. Comparative bioequivalence study of rifampicin and isoniazid combinations in healthy volunteers.
Padgaonkar KA; Revankar SN; Bhatt AD; Vaz JA; Desai ND; D'Sa S; Shah V; Gandewar K
Int J Tuberc Lung Dis; 1999 Jul; 3(7):627-31. PubMed ID: 10423226
[TBL] [Abstract][Full Text] [Related]
40. Bioequivalence of fixed-dose combination Myrin®-P Forte and reference drugs in loose combination.
Wang HF; Wang R; O'Gorman M; Crownover P; Naqvi A; Jafri I
Int J Tuberc Lung Dis; 2013 Dec; 17(12):1596-601. PubMed ID: 24200275
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
